Everest Medicines Closes Licensing Deal with Travere for Civorebrutinib

Corporate Action
โดย PR Newswire·Read original
Summary · why it matters

Everest Medicines has closed its exclusive licensing agreement with Travere Therapeutics for the development and commercialization of civorebrutinib, a potential best-in-class oral BTK inhibitor, in the U.S. and global markets outside Greater China and select Asian countries. Everest receives an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in milestone payments across up to five indications, plus tiered royalties ranging from high single-digit to double-digit percentages on future sales.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
Everest Medicines Ltd
1952
▲ PositiveTechnologyrelevance

Everest closes exclusive licensing deal for civorebrutinib, a potential best-in-class BTK inhibitor, gaining rights to develop and commercialize in U.S. and global markets.

Travere Therapeutics Inc
TVTX
▲ PositiveCapitalrelevance

Travere receives $112.5M upfront and up to $1.03B in milestones plus royalties for licensing civorebrutinib to Everest.

© 2026 MarketDXNews